Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen Follows Through On Warning It May Have To Liquidate

Executive Summary

Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.


Related Content

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Obesity Market Gains Weight But Better Drugs Still Needed
Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales
Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye
Takeda Exits Contrave Deal But Orexigen Insists Drug Can Grow
CEO Zook exits Vivus, J&J's Fischer steps in
New Vivus board appoints Zook as CEO


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts